Address: 823 Jays Drive
Lansdale, PA 19446,United States of America
Tel:
Web: http://www.jdptherapeutics.com/default.aspx
JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life-threatening diseases with significant unmet medical needs, primarily for use in acute care in a hospital setting.
Small Molecule Therapeutics
2025 was a year of volatility for pharma and healthcare. In particular, the speed with which the administration of Donald Trump makes (and often then changes) consequential policy decisions has…
Michael Pearlmutter, CEO of the EveryLife Foundation for Rare Diseases (the EveryLife Foundation), brings a deeply personal motivation and commitment to driving meaningful change for the rare disease community. In…
Matt Shaulis, General Manager for North America at BeOne Medicines, discusses the company’s rapid rise as a global oncology leader and its growing impact in the US. He explains how…
Spiro Gavaris, President of Lupin’s US generics business, shares a candid assessment of the shifting dynamics shaping today’s generic and biosimilar landscape. He outlines how Lupin is positioning itself for…
Kelly LoBianco, founding director of the Los Angeles County Department of Economic Opportunity, discusses how the agency is driving growth of the region’s life sciences sector. She outlines LA County’s…
Lonza’s transformation under the One Lonza Strategy comes at a moment of significant change for the global biologics and CDMO sectors. Gordon Bates, Head of Integrated Biologics, reflects on the…
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
Dr Jerry Vockley, Director of the Center for Rare Disease Therapy and Chief of the Division of Medical Genetics at UPMC Children’s Hospital of Pittsburgh, offers a look at the…
Michael Petroutsas, President and Head of Astellas Pharma US, reflects on the company’s ongoing transformation and the market’s growing strategic importance within Astellas’ global organisation. He goes on to highlight…
Once centred on building awareness, the Alliance for Regenerative Medicine has grown into the world’s foremost advocate for the cell and gene therapy sector, bringing together more than 400 members…
Global pharma is rushing to relocate manufacturing to the US. To reduce dependence on foreign manufacturing sources – most notably from its main economic adversary, China – the Trump administration…
First published in the September/October 2025 edition of ISPOR’s Value & Outcomes Spotlight, David Thompson (Rubidoux Research), Christopher Blanchette (Clinical, Medical and Regulatory Affairs), and Stephanie Earnshaw (Access Strategy Consulting)…
See our Cookie Privacy Policy Here
